85 related articles for article (PubMed ID: 26055204)
1. New surgical staging system for patients with recurrent nasopharyngeal carcinoma based on the AJCC/UICC rTNM classification system.
You R; Zou X; Wang SL; Jiang R; Tang LQ; Zhang WD; Li L; Zhang MX; Shen GP; Guo L; Qian CN; Mai HQ; Ma J; Hong MH; Chen MY
Eur J Cancer; 2015 Sep; 51(13):1771-9. PubMed ID: 26055204
[TBL] [Abstract][Full Text] [Related]
2. A novel endoscopic nasopharyngectomy by low-temperature plasma radiofrequency ablation in localized recurrent nasopharyngeal carcinoma.
Zou X; Feng ZK; Hua YJ; Liu YP; Xie YL; Ouyang YF; Liu YL; Wang ZQ; You R; Ding X; Yang Q; Yu ZK; Huang PY; Wang SL; Chen MY
Head Neck; 2024 Feb; 46(2):291-299. PubMed ID: 37974339
[TBL] [Abstract][Full Text] [Related]
3. Preliminary evidence for endoscopic surgery combined with postoperative anti-PD-1 immunotherapy in advanced recurrent nasopharyngeal carcinoma.
Xu H; Li W; Zhang H; Wang H; Hu L; Gu Y; Wang D
BMC Cancer; 2023 Dec; 23(1):1259. PubMed ID: 38129782
[TBL] [Abstract][Full Text] [Related]
4. Research trends and hotspots in surgical treatment of recurrent nasopharyngeal carcinoma: A bibliometric analysis from 2000 to 2023.
Wu Z; Chen Y; Yu G; Ma Y
Asian J Surg; 2024 Jun; 47(6):2939-2941. PubMed ID: 38431480
[No Abstract] [Full Text] [Related]
5. Tumour volume measurement in head and neck cancer.
Chong VF
Cancer Imaging; 2007 Oct; 7 Spec No A(Special issue A):S47-9. PubMed ID: 17921082
[TBL] [Abstract][Full Text] [Related]
6. [Discussion on the surgical treatment of nasopharyngeal carcinoma].
Kong W
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2023 Jul; 37(7):507-518. PubMed ID: 37549941
[No Abstract] [Full Text] [Related]
7. Recommendations for surgical management of recurrent nasopharyngeal carcinoma during COVID-19 pandemic.
Chow VLY; Chan JYW; Wong STS; Wei WI
Laryngoscope Investig Otolaryngol; 2020 Jun; 5(3):468-472. PubMed ID: 32596489
[TBL] [Abstract][Full Text] [Related]
8. Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079).
Ma BB; Goh BC; Lim WT; Hui EP; Tan EH; Lopes Gde L; Lo KW; Li L; Loong H; Foster NR; Erlichman C; King AD; Kam MK; Leung SF; Chan KC; Chan AT
Invest New Drugs; 2015 Aug; 33(4):985-91. PubMed ID: 26084990
[TBL] [Abstract][Full Text] [Related]
9. Pregnancy associated nasopharyngeal carcinoma: A retrospective case-control analysis of maternal survival outcomes.
Cheng YK; Zhang F; Tang LL; Chen L; Zhou GQ; Zeng MS; Kang TB; Jia WH; Shao JY; Mai HQ; Guo Y; Ma J
Radiother Oncol; 2015 Jul; 116(1):125-30. PubMed ID: 26104977
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic efficacy of doxorubicin delivery by a CO2 generating liposomal platform in breast carcinoma.
Han HD; Jeon YW; Kwon HJ; Jeon HN; Byeon Y; Lee CO; Cho SH; Shin BC
Acta Biomater; 2015 Sep; 24():279-285. PubMed ID: 26102337
[TBL] [Abstract][Full Text] [Related]
11. Preclinical evaluation of PI3K inhibitor BYL719 as a single agent and its synergism in combination with cisplatin or MEK inhibitor in nasopharyngeal carcinoma (NPC).
Wong CH; Ma BB; Cheong HT; Hui CW; Hui EP; Chan AT
Am J Cancer Res; 2015; 5(4):1496-506. PubMed ID: 26101713
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer.
Chua C; Tan IB; Yamada Y; Rha SY; Yong WP; Ong WS; Tham CK; Ng M; Tai DW; Iwasa S; Lim HY; Choo SP
Cancer Chemother Pharmacol; 2015 Aug; 76(2):397-408. PubMed ID: 26099969
[TBL] [Abstract][Full Text] [Related]
13. Profiling of Oncogenic Driver Events in Lung Adenocarcinoma Revealed MET Mutation as Independent Prognostic Factor.
Yeung SF; Tong JHM; Law PPW; Chung LY; Lung RWM; Tong CYK; Chow C; Chan AWH; Wan IYP; Mok TSK; To KF
J Thorac Oncol; 2015 Sep; 10(9):1292-1300. PubMed ID: 26098749
[TBL] [Abstract][Full Text] [Related]
14. SOX9 was involved in TKIs resistance in renal cell carcinoma via Raf/MEK/ERK signaling pathway.
Li XL; Chen XQ; Zhang MN; Chen N; Nie L; Xu M; Gong J; Shen PF; Su ZZ; Weng X; Tan JY; Zhao T; Zeng H; Zhou Q
Int J Clin Exp Pathol; 2015; 8(4):3871-81. PubMed ID: 26097571
[TBL] [Abstract][Full Text] [Related]
15. Peri-operative chemotherapy for patients with resectable colorectal hepatic metastasis: A meta-analysis.
Wang ZM; Chen YY; Chen FF; Wang SY; Xiong B
Eur J Surg Oncol; 2015 Sep; 41(9):1197-203. PubMed ID: 26094113
[TBL] [Abstract][Full Text] [Related]
16. Feasibility and Timing of Cytoreduction Surgery in Advanced (Metastatic or Recurrent) Gastrointestinal Stromal Tumors During the Era of Imatinib.
Chang SC; Liao CH; Wang SY; Tsai CY; Chiang KC; Cheng CT; Yeh TS; Chen YY; Ma MC; Liu CT; Yeh CN
Medicine (Baltimore); 2015 Jun; 94(24):e1014. PubMed ID: 26091448
[TBL] [Abstract][Full Text] [Related]
17. Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose.
Venkatakrishnan K; Kim TM; Lin CC; Thye LS; Chng WJ; Ma B; Chen MH; Zhou X; Liu H; Kelly V; Kim WS
Invest New Drugs; 2015 Aug; 33(4):942-53. PubMed ID: 26084989
[TBL] [Abstract][Full Text] [Related]
18. Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer.
Kwon YJ; Petrie K; Leibovitch BA; Zeng L; Mezei M; Howell L; Gil V; Christova R; Bansal N; Yang S; Sharma R; Ariztia EV; Frankum J; Brough R; Sbirkov Y; Ashworth A; Lord CJ; Zelent A; Farias E; Zhou MM; Waxman S
Mol Cancer Ther; 2015 Aug; 14(8):1824-36. PubMed ID: 26078298
[TBL] [Abstract][Full Text] [Related]
19. Characteristics and behaviour of screen-detected ductal carcinoma in situ of the breast: comparison with symptomatic patients.
Koh VC; Lim JC; Thike AA; Cheok PY; Thu MM; Tan VK; Tan BK; Ong KW; Ho GH; Tan WJ; Tan Y; Salahuddin AS; Busmanis I; Chong AP; Iqbal J; Thilagaratnam S; Wong JS; Tan PH
Breast Cancer Res Treat; 2015 Jul; 152(2):293-304. PubMed ID: 26077641
[TBL] [Abstract][Full Text] [Related]
20. The effect of BIM deletion polymorphism on intrinsic resistance and clinical outcome of cancer patient with kinase inhibitor therapy.
Ying HQ; Chen J; He BS; Pan YQ; Wang F; Deng QW; Sun HL; Liu X; Wang SK
Sci Rep; 2015 Jun; 5():11348. PubMed ID: 26076815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
